Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury

Transplantation

Volumn 90, Issue 12, 2010, Pages 1260-1264

  Rajakumar, Siddharth V ^a,b   Lu, Bo ^a   Crikis, Sandra ^a   Robson, Simon C ^c   D'Apice, Anthony J F ^a,b   Cowan, Peter J ^a,b   Dwyer, Karen M ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenosine; Adenosine monophosphate; CD39; CD73; Kidney ischemia reperfusion injury

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE 5' (ALPHA,BETA METHYLENE)DIPHOSPHATE; CD39 ANTIGEN; CREATININE; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; TRANSGENIC ANIMAL; WILD TYPE;

5'-NUCLEOTIDASE; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; CREATININE; DISEASE MODELS, ANIMAL; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; REPERFUSION INJURY;

EID: 78650830583     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182003d9b     Document Type: Article

References (36)

1. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
2. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130: 41.
3. Lappas CM, Day YJ, Marshall MA, et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203: 2639.
4. Rabb H. The T cell as a bridge between innate and adaptive immune systems: Implications for the kidney. Kidney Int 2002; 61: 1935.
5. Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112: 883.
6. Grenz A, Osswald H, Eckle T, et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008; 5: e137.
7. Lee HT, Gallos G, Nasr SH, et al. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemiareperfusion injury in mice. J Am Soc Nephrol 2004; 15: 102.
8. Weissmuller T, Eltzschig HK, Colgan SP. Dynamic purine signaling and metabolism during neutrophil-endothelial interactions. Purinergic Signal 2005; 1: 229.
9. Lee HT, Emala CW. Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation.AmJ Kidney Dis 2001; 38: 610.
10. Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: The role of CD4- T cells and IFN-gamma. J Immunol 2006; 176: 3108.
11. Kishore BK, Isaac J, Fausther M, et al. Expression of NTPDase1 and NTPDase2 in murine kidney: Relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 2005; 288: F1032.
12. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257.
13. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression ofCD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant no. doi: 10.1111/j.1600-6143.2010.03257.x.
14. Lu B, Rajakumar SV, Robson SC, et al. The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation 2008; 86: 1707.
15. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007; 21: 2863.
16. Hart ML, Gorzolla IC, Schittenhelm J, et al. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol 2010; 184: 4017.
17. Eckle T, Fullbier L, Wehrmann M, et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 2007; 178: 8127.
18. Guckelberger O, Sun XF, Sevigny J, et al. Beneficial effects of CD39/ ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 2004; 91: 576.
19. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5- nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004; 200: 1395.
20. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993.
21. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998; 161: 95.
22. Airas L, Niemela J, Jalkanen S. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J Immunol 2000; 165: 5411.
23. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood 2004; 104: 3986.
24. Dianzani U, Redoglia V, Bragardo M, et al. Co-stimulatory signal delivered by CD73 molecule to human CD45RAhiCD45ROlo (naive) CD8- T lymphocytes. J Immunol 1993; 151: 3961.
25. Airas L, Hellman J, Salmi M, et al. CD73 is involved in lymphocyte binding to the endothelium: Characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 1995; 182: 1603.
26. Grenz A, Zhang H, Eckle T, et al. Protective role of ecto-5- nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 2007; 18: 833.
27. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5- nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115: 1581.
28. Van Waarde A, Stromski ME, Thulin G, et al. Protection of the kidney against ischemic injury by inhibition of 5- nucleotidase. Am J Physiol 1989; 256(2 pt 2): F298.
29. Grenz A, Eckle T, Zhang H, et al. Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice. Am J Physiol Renal Physiol 2007; 292: F475.
30. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440.
31. Qi AD, Harden TK, Nicholas RA. GPR80/99, proposed to be the P2Y(15) receptor activated by adenosine and AMP, is not a P2Y receptor. Purinergic Signal 2004; 1: 67.
32. Young LH, Li J, Baron SJ, et al. AMP-activated protein kinase: A key stress signaling pathway in the heart. Trends Cardiovasc Med 2005; 15: 110.
33. Russell RR III, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495.
34. Peralta C, Bartrons R, Serafin A, et al. Adenosine monophosphateactivated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology 2001; 34: 1164.
35. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006; 58: 58.
36. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897.